2025.03.21
On March 21, 2025, VISEN Pharmaceuticals (VISEN) with the stock code 2561.HK, issued 9,900,000 ordinary shares and was listed on the Main Board of the Hong Kong Stock Exchange. VISEN was established in November 2018 and is a late-stage biopharmaceutical company with products nearing commercialization. It provides treatment solutions for endocrine diseases in China (including Hong Kong, Macau and Taiwan).
As VISEN's PRC legal counsel, JunHe provided legal services for its Hong Kong IPO, including: (1) conducting legal due diligence in China, issuing Chinese legal opinions, reviewing and amending the prospectus and the related application and offering documents for the IPO, and responding to the PRC law related issues raised by the SFC; (2) drafting the full set of documents for filing with the CSRC for the overseas listing, including the filing report and legal opinions, in accordance with the CSRC requirements, and responding to issues raised by the CSRC.
This project spanned several years during which time the CSRC issued various regulations regarding overseas listings. The JunHe team maintained effective communication and close cooperation with the other intermediaries throughout the project and provided high-quality, rigorous and efficient legal services. VISEN successfully completed the filing with the CSRC for its overseas listing and obtained approval for its IPO application from the Hong Kong Stock Exchange and the SFC.
Partners TANG, Jie and TAO, Xudong led the JunHe team and partner XU, Shengao (Shaun) was responsible for the specific work. Partner LAO, Chengzhe provided support for the internal control matters.
